NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $65.11 +0.27 (+0.42 %) (As of 03/19/2019 01:00 PM ET)Previous Close$64.84Today's Range$64.32 - $66.6852-Week Range$41.63 - $99.82Volume187,666 shsAverage Volume457,494 shsMarket Capitalization$3.80 billionP/E Ratio-10.80Dividend YieldN/ABeta2.38 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts. Receive AGIO News and Ratings via Email Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGIO Previous Symbol CUSIPN/A CIK1439222 Webwww.agios.com Phone617-649-8600Debt Debt-to-Equity RatioN/A Current Ratio6.56 Quick Ratio6.56Price-To-Earnings Trailing P/E Ratio-10.80 Forward P/E Ratio-9.81 P/E GrowthN/A Sales & Book Value Annual Sales$94.39 million Price / Sales40.28 Cash FlowN/A Price / Cash FlowN/A Book Value$11.82 per share Price / Book5.51Profitability EPS (Most Recent Fiscal Year)($6.03) Net Income$-346,020,000.00 Net Margins-366.61% Return on Equity-44.13% Return on Assets-36.18%Miscellaneous EmployeesN/A Outstanding Shares58,400,000Market Cap$3.80 billion Next Earnings Date5/3/2019 (Estimated) OptionableOptionable Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions What is Agios Pharmaceuticals' stock symbol? Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO." How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals Inc (NASDAQ:AGIO) posted its quarterly earnings results on Thursday, February, 14th. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.65) by $0.07. The biopharmaceutical company had revenue of $30 million for the quarter, compared to the consensus estimate of $19.98 million. Agios Pharmaceuticals had a negative net margin of 366.61% and a negative return on equity of 44.13%. The company's revenue for the quarter was up 200.0% on a year-over-year basis. During the same period last year, the firm posted ($1.81) earnings per share. View Agios Pharmaceuticals' Earnings History. When is Agios Pharmaceuticals' next earnings date? Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, May 3rd 2019. View Earnings Estimates for Agios Pharmaceuticals. What price target have analysts set for AGIO? 11 brokers have issued 12 month target prices for Agios Pharmaceuticals' stock. Their predictions range from $80.00 to $123.00. On average, they expect Agios Pharmaceuticals' share price to reach $97.8571 in the next year. This suggests a possible upside of 50.3% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals. What is the consensus analysts' recommendation for Agios Pharmaceuticals? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals. What are Wall Street analysts saying about Agios Pharmaceuticals stock? Here are some recent quotes from research analysts about Agios Pharmaceuticals stock: 1. According to Zacks Investment Research, "Agios depends heavily on Celgene for revenues, which it earns in the form of collaboration revenues and royalty revenues on Idhifa sales. Stiff competition from large pharmaceutical companies including AstraZeneca, Bayer, Eli Lilly, Roche, GlaxoSmithKline, Merck, Pfizer and Sanofi is another matter of concern for the company. Shares of the company have underperformed the industry in 2018. Nevertheless, Agios' first wholly owned precision medicine, Tibsovo, was approved by the FDA for treating AML. The drug has generated strong sales in the very first quarter following its FDA nod. The company is also focused on expanding the label for Tibsovo to advance its cancer and rare genetic disease clinical development programs.Loss estimates have widened slighty ahead of the Q4 earnings release. Agios has a mixed record of earnings surprises in recent quarters. " (2/12/2019) 2. Canaccord Genuity analysts commented, "We maintain a favorable view on Fouse as the CEO given her expensive experience at Laboratories, holding various senior roles focusing on corporate strategies, finance, and operations. We believe Fouse will help maintain AGIO’s heading in launching the approved products and developing the pipeline." (9/5/2018) 3. Needham & Company LLC analysts commented, "BeiGene announced the pricing of its Hong Kong initial public offering of 65,600,000 ordinary shares. Based on the assumed exchange rate, the public offering, priced at $13.76 (HK$108) per share or $178.9 per American Depositary Share (ADS) is expected to raise ~$903M (HK$7.08bn)." (8/2/2018) Has Agios Pharmaceuticals been receiving favorable news coverage? Media headlines about AGIO stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agios Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the stock's share price in the near future. Who are some of Agios Pharmaceuticals' key competitors? Some companies that are related to Agios Pharmaceuticals include Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Marina Biotech (MRNA) and Perrigo (PRGO). What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Netflix (NFLX), Intercept Pharmaceuticals (ICPT), Alibaba Group (BABA), Tesla (TSLA), Biogen (BIIB), Micron Technology (MU), bluebird bio (BLUE) and Allergan (AGN). Who are Agios Pharmaceuticals' key executives? Agios Pharmaceuticals' management team includes the folowing people: Dr. David P. Schenkein, Pres & Exec. Chairman (Age 62)Dr. Jacqualyn A. Fouse, CEO & Director (Age 58)Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 70)Mr. Andrew Hirsch, Chief Financial Officer (Age 48)Dr. Scott A. Biller Ph.D., Chief Scientific Officer (Age 63) Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (14.94%), BlackRock Inc. (5.71%), BB Biotech AG (4.95%), First Trust Advisors LP (2.32%), Baillie Gifford & Co. (1.48%) and Geode Capital Management LLC (0.94%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Celgene European Investment Co, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, John Maraganore, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals. Which major investors are selling Agios Pharmaceuticals stock? AGIO stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Polar Capital LLP, Casdin Capital LLC, Squarepoint Ops LLC, Rhenman & Partners Asset Management AB, California Public Employees Retirement System, TD Asset Management Inc. and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, David P Schenkein, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals. Which major investors are buying Agios Pharmaceuticals stock? AGIO stock was bought by a variety of institutional investors in the last quarter, including BB Biotech AG, Norges Bank, Baillie Gifford & Co., First Trust Advisors LP, Millennium Management LLC, Two Sigma Investments LP, American Century Companies Inc. and Geode Capital Management LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Celgene European Investment Co, Corp /De/ Celgene and David Scadden. View Insider Buying and Selling for Agios Pharmaceuticals. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Agios Pharmaceuticals' stock price today? One share of AGIO stock can currently be purchased for approximately $65.11. How big of a company is Agios Pharmaceuticals? Agios Pharmaceuticals has a market capitalization of $3.80 billion and generates $94.39 million in revenue each year. The biopharmaceutical company earns $-346,020,000.00 in net income (profit) each year or ($6.03) on an earnings per share basis. What is Agios Pharmaceuticals' official website? The official website for Agios Pharmaceuticals is http://www.agios.com. How can I contact Agios Pharmaceuticals? Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected] MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 345 (Vote Outperform)Underperform Votes: 299 (Vote Underperform)Total Votes: 644MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: Why do company’s buyback their stock?